Stocks Health care TNYA
NASDAQ · Health careTenaya Therapeutics, Inc. (TNYA)
It posted a net loss of $101.8M. In fiscal 2025 capital spending exceeded operating cash flow by $68.9M. At September 30, 2026 it held $66.8M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 4, 2026.
Key facts about Tenaya Therapeutics, Inc.
- Net worth
- Tenaya Therapeutics, Inc. has a market value (market cap) of $88.3M at the latest share price, and shareholders' equity of $54.5M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $68.3M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 4, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Tenaya Therapeutics, Inc.'s next report is expected around March 10, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Tenaya Therapeutics, Inc. does
Tenaya Therapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker TNYA.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$90.6M | -$0.59 | -$68.9M |
| 2024 | n/a | -$111.1M | -$1.31 | -$91.5M |
| 2023 | n/a | -$124.1M | -$1.68 | -$103.3M |
| 2022 | n/a | -$123.7M | -$2.76 | -$125.1M |
| 2021 | n/a | -$72.7M | -$4.10 | -$85.9M |
| 2021 | n/a | -$38.4M | -$39.50 | -$45.2M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Tenaya Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 4, 2026Quarterly report 10-Q · period to September 30, 2026Revenue was $1.7M; diluted EPS -$0.08 versus -$0.12.
- November 4, 2026
- October 23, 2026Additional proxy material DEFA14A
- October 23, 2026Proxy statement DEF 14A
- October 13, 2026Preliminary proxy statement PRE 14A
- August 24, 2026Passive stake (5% or more) SCHEDULE 13G
- August 5, 2026
- August 5, 2026
- August 5, 2026
- July 2, 2026
Insider trades
What the people running Tenaya Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $21K worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 10, 2026 | Tingley WhittemoreChief Medical Officer | Received as pay | 49,000 | - |
| September 10, 2026 | Ali FarazChief Executive Officer, Director | Received as pay | 122,000 | - |
| August 17, 2026 | Tingley WhittemoreChief Medical Officer | Sold | 1,637 | $1.2K |
| August 17, 2026 | Tingley WhittemoreChief Medical Officer | Sold | 1,637 | $1.2K |
| August 17, 2026 | Tingley WhittemoreChief Medical Officer | Sold | 1,871 | $1.3K |
| August 17, 2026 | Tingley WhittemoreChief Medical Officer | Sold | 2,279 | $1.6K |
| August 17, 2026 | Ali FarazChief Executive Officer, Director | Sold | 5,837 | $4.1K |
| August 17, 2026 | Ali FarazChief Executive Officer, Director | Sold | 3,969 | $2.8K |
Who owns TNYA
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| The Column Group Opportunity III, LP13D, may seek influence with 7 related filers | 23.1% | February 26, 2026 |
| Millennium Management LLC13G, passive with 3 related filers | 5.2% | August 24, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 101 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Vanguard Capital Management LLC | 7,101,263 | -1,381,025 |
| Millennium Management LLC | 6,429,648 | +972,982 |
| Citadel Advisors LLC | 4,566,774 | +366,774 |
| Renaissance Technologies LLC | 4,281,100 | +567,339 |
| BlackRock, Inc. | 4,008,719 | +304,764 |
| Empery Asset Management, LP | 3,863,115 | -423,818 |
| Marshall Wace, Llp | 3,503,178 | +797,788 |
| Burkehill Global Management, LP | 2,000,000 | 0 |
| Geode Capital Management, LLC | 1,834,674 | +274,735 |
| ADAR1 Capital Management, LLC | 1,555,500 | +47,700 |
| Raiffeisen Bank International AG | 1,200,000 | +200,000 |
| Euclidean Capital LLC | 1,015,705 | 0 |
| Vanguard Fiduciary Trust Co | 987,505 | -28,197 |
| Mirador Capital Partners LP | 905,097 | +18,180 |
| State Street Corp | 708,721 | 0 |
| Squarepoint Ops LLC | 659,247 | +310,979 |
| StepStone Group LP | 462,163 | 0 |
| UBS Group AG | 456,555 | -208,625 |
| Jane Street Group, LLC | 450,435 | -729,646 |
| Two Sigma Investments, LP | 380,790 | -899,600 |
Insiders
3 insiders reported holding 921,122 shares in total, about $341.7K at the last price.
| Holder | Shares |
|---|---|
| Ali FarazChief Executive Officer, Director | 539,782 |
| Tingley WhittemoreChief Medical Officer | 263,073 |
| Higa TomohiroSVP, Finance | 118,267 |
Questions about TNYA
What does Tenaya Therapeutics, Inc. do?
Tenaya Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as TNYA. Its shares trade on NASDAQ under the ticker TNYA.
What is Tenaya Therapeutics, Inc.'s net worth?
Tenaya Therapeutics, Inc. has a market value (market cap) of $88.3M at the latest share price, and shareholders' equity of $54.5M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Tenaya Therapeutics, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $101.8M.
When did Tenaya Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 4, 2026. It covers the period to September 30, 2026.
When is Tenaya Therapeutics, Inc.'s next earnings report?
Tenaya Therapeutics, Inc.'s next report is expected around March 10, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare TNYA with
Follow TNYA
Get an email when Tenaya Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Tenaya Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.